Related Experiment Video

Updated: May 25, 2026

Evaluating In Vitro DNA Damage Using Comet Assay
10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

Targeted therapy for brain tumours: role of PARP inhibitors

C Leonetti1, A Biroccio, G Graziani

  • 1Experimental Chemotherapy Laboratory, Regina Elena Cancer Institute, Rome, Italy. leonetti@ifo.it

Current Cancer Drug Targets
|January 25, 2012
PubMed

Insights

Poly(ADP-ribose) polymerase (PARP) inhibitors show promise for treating brain tumors by enhancing chemotherapy and radiation. These inhibitors also exhibit anti-cancer effects in BRCA-mutated cancers and may reduce tumor growth through anti-angiogenesis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Malignant gliomas and brain metastases have poor prognoses despite advances in targeted therapies.
  • Poly(ADP-ribose) polymerase (PARP) inhibitors represent a novel therapeutic class with potential in monotherapy or combination treatments.

Purpose of the Study:

  • To review the therapeutic implications of targeting PARP in brain tumor treatment.
  • To discuss the role of PARP inhibitors in enhancing current treatment regimens and their potential anti-tumor mechanisms.

Main Methods:

  • Review of existing literature on PARP inhibitors and their mechanisms of action.
  • Analysis of preclinical and clinical data regarding PARP inhibition in brain tumors.
  • Discussion of the role of PARP-1 and PARP-2 in DNA repair pathways.

Main Results:

  • PARP inhibitors enhance the efficacy of DNA-damaging agents like temozolomide and ionizing radiation.
  • PARP inhibitors demonstrate cytotoxic effects in BRCA-mutated tumors by exploiting homologous recombination repair defects.
  • PARP inhibition may exert anti-angiogenic effects, contributing to tumor growth impairment.

Conclusions:

  • Targeting PARP offers a promising strategy for developing new treatment regimens for primary and secondary brain tumors.
  • Ongoing clinical trials are evaluating the efficacy of PARP inhibitors across various advanced solid tumors.
  • Further research into PARP inhibition could significantly improve outcomes for brain tumor patients.

More Related Videos

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.